Physician profile
Jonathan C Bender
NPI 1649228651
$4,360.36
in general payments reported to CMS, 2019-2025
49 companies · $697 in 2025
The $697 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $221 · 2021: $66.83 · 2022: $520 · 2023: $1,218 · 2024: $805 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,702 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,701.77 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mckesson Specialty Care Distribution, LLC | $403.00 | 2019-2020 | |
| Abbvie INC. | $389.05 | 2023-2025 | Venclexta |
| Merck Sharp & Dohme LLC | $326.22 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $269.85 | 2019-2025 | Darzalex, Imbruvica, Rybrevant |
| Gilead Sciences, INC. | $268.68 | 2021-2025 | Trodelvy |
| Daiichi Sankyo INC. | $223.49 | 2022-2025 | Enhertu, Datroway |
| Regeneron Healthcare Solutions, INC. | $198.68 | 2022-2024 | Libtayo |
| Novartis Pharmaceuticals Corporation | $197.44 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $160.42 | 2019-2025 | Lynparza |
| Stemline Therapeutics INC. | $150.90 | 2023-2025 | Orserdu |
| Pfizer INC. | $149.14 | 2022-2025 | |
| Astellas Pharma US INC | $135.18 | 2019-2025 | Padcev, Xospata |
| Genzyme Corporation | $106.65 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $105.90 | 2023-2025 | Ninlaro, Fruzaqla |
| Amgen INC. | $100.33 | 2019-2023 | Nplate, Vectibix, Xgeva |
Show all 49 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rigel Pharmaceuticals, INC. | $90.82 | 2019-2023 | Rezlidhia, Tavalisse |
| E.R. Squibb & Sons, L.L.C. | $90.40 | 2019-2024 | Opdualag |
| Array Biopharma INC | $82.03 | 2019-2025 | Mektovi, Tukysa, Braftovi |
| Seagen INC. | $73.76 | 2022-2023 | Adcetris, Padcev |
| Genentech USA, INC. | $71.51 | 2023-2024 | Tecentriq, Alecensa, Rozlytrek |
| Pharmacyclics LLC, An Abbvie Company | $70.87 | 2022 | |
| Glaxosmithkline, LLC. | $67.72 | 2025 | Ojjaara, Blenrep |
| Foundation Medicine, INC. | $60.10 | 2022-2023 | Foundationone Cdx |
| Bayer Healthcare Pharmaceuticals INC. | $52.25 | 2022-2024 | |
| Mirati Therapeutics, INC. | $45.97 | 2023-2024 | Krazati |
| Celgene Corporation | $37.92 | 2019-2023 | Opdualag |
| Karyopharm Therapeutics INC. | $33.48 | 2020-2023 | Xpovio |
| Alexion Pharmaceuticals, INC. | $30.92 | 2021-2024 | Ultomiris |
| Tersera Therapeutics LLC | $28.37 | 2024 | Zoladex |
| Janssen Pharmaceuticals, INC | $24.15 | 2019-2022 | |
| Springworks Therapeutics, INC. | $22.71 | 2024 | Ogsiveo |
| Ipsen Biopharmaceuticals, INC | $21.41 | 2024 | Onivyde |
| Legend Biotech USA INC. | $20.11 | 2025 | Carvykti |
| Puma Biotechnology, INC. | $19.48 | 2023 | |
| G1 Therapeutics, INC. | $19.19 | 2023 | Cosela |
| Epizyme, INC. | $19.07 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $17.70 | 2019 | |
| Pharmaessentia USA Corporation | $17.45 | 2025 | Besremi |
| Kite Pharma, INC. | $16.78 | 2023 | Yescarta |
| Csl Behring | $16.05 | 2024 | Hizentra |
| Recordati_rare_diseases_inc. | $15.90 | 2023 | Sylvant |
| Lilly USA, LLC | $15.61 | 2023 | Verzenio, Jaypirca, Retevmo |
| Fennec Pharmaceuticals, INC. | $15.52 | 2025 | Fyarro |
| Advanced Accelerator Applications | $14.37 | 2019 | |
| Dendreon Pharmaceuticals LLC | $13.82 | 2024 | Provenge |
| Amag Pharmaceuticals, INC. | $13.30 | 2019 | |
| Cti Biopharma Corp. | $12.86 | 2023 | Vonjo |
| Octapharma USA, INC. | $12.39 | 2022 | |
| Exelixis INC. | $11.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Bender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.